{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:31:35Z","timestamp":1792359095158,"version":"4.4.0"},"reference-count":105,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016131","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T02:18:24Z","timestamp":1759112304000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of respiratory syncytial virus vaccines"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8702-7094","authenticated-orcid":false,"given":"KM","family":"Saif-Ur-Rahman","sequence":"additional","affiliation":[{"name":"Evidence Synthesis Ireland and Cochrane Ireland; University of Galway; Galway Ireland"},{"name":"Centre for Health Research Methods, School of Nursing and Midwifery; University of Galway; Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"King","sequence":"additional","affiliation":[{"name":"Department of Clinical and Laboratory Immunology; St James's Hospital; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u00e1n Olann","family":"Whelan","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology; Children's Health Ireland at Temple Street; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Blair","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases; Cork University Hospital; Cork Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u00e1n","family":"Donohue","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases; St Vincent's University Hospital; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caoimhe","family":"Madden","sequence":"additional","affiliation":[{"name":"Evidence Synthesis Ireland and Cochrane Ireland; University of Galway; Galway Ireland"},{"name":"Centre for Health Research Methods, School of Nursing and Midwifery; University of Galway; Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Kothari","sequence":"additional","affiliation":[{"name":"Consultant to Evidence Synthesis Ireland and Cochrane Ireland; University of Galway; Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isolde","family":"Sommer","sequence":"additional","affiliation":[{"name":"Cochrane Austria, Department for Evidence-based Medicine and Evaluation; University for Continuing Education Krems; Krems Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harder","sequence":"additional","affiliation":[{"name":"Immunisation Unit; Robert Koch Institute; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dauby","sequence":"additional","affiliation":[{"name":"Infectious Diseases; CHU Saint Pierre, Universit\u00e9 Libre de Bruxelles (ULB); Brussels Belgium"},{"name":"Center for Environmental Health and Occupational Health; School of Public Health, Universit\u00e9 Libre de Bruxelles (ULB); Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Rask","family":"Moustsen-Helms","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology and Prevention; Statens Serum Institut; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Ruta","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy; Bucharest Romania"},{"name":"Stefan S. Nicolau Institute of Virology; Bucharest Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fr\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; CHU de Li\u00e8ge, Li\u00e8ge University; Li\u00e8ge Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Sch\u00f6nfeld","sequence":"additional","affiliation":[{"name":"Immunisation Unit; Robert Koch Institute; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Poukka","sequence":"additional","affiliation":[{"name":"Department of Public Health; Finnish Institute for Health and Welfare; Helsinki Finland"},{"name":"Department of Public Health; Faculty of Medicine, University of Helsinki; Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irja","family":"Lutsar","sequence":"additional","affiliation":[{"name":"Medical Microbiology; University of Tartu; Tartu Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Olsson","sequence":"additional","affiliation":[{"name":"European Centre for Disease Prevention and Control; Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Melidou","sequence":"additional","affiliation":[{"name":"European Centre for Disease Prevention and Control; Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Adel Ali","sequence":"additional","affiliation":[{"name":"European Centre for Disease Prevention and Control; Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Dwan","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Devane","sequence":"additional","affiliation":[{"name":"Evidence Synthesis Ireland and Cochrane Ireland; University of Galway; Galway Ireland"},{"name":"Centre for Health Research Methods, School of Nursing and Midwifery; University of Galway; Galway Ireland"},{"name":"HRB-Trials Methodology Research Network; University of Galway; Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"10.1002\/14651858.CD016131-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Kimberlin DW Barnett ED Lynfield R Sawyer MH Respiratory syncytial virus. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases https:\/\/publications.aap.org\/redbook\/book\/347\/Red-Book-2021-2024","DOI":"10.1542\/9781610025225"},{"issue":"4","key":"10.1002\/14651858.CD016131-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","article-title":"The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study","volume":"11","author":"Wildenbeest","year":"2023","journal-title":"Lancet Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016131-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00431-014-2415-2","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with congenital heart disease","volume":"6","author":"Checchia","year":"2017","journal-title":"Infectious Diseases and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD016131-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00431-014-2415-2","article-title":"RSV infection among children born moderately preterm in a community-based cohort","volume":"174","author":"Gijtenbeek","year":"2015","journal-title":"European Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD016131-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40121-017-0160-3","article-title":"Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases","volume":"6","author":"Manzoni","year":"2017","journal-title":"Infectious Diseases and Therapy"},{"key":"10.1002\/14651858.CD016131-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD016131-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"104493","DOI":"10.1016\/j.ebiom.2023.104493","article-title":"The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study","volume":"90","author":"Dagan","year":"2023","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1002\/14651858.CD016131-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/jpc.16197","article-title":"Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions","volume":"58","author":"Binns","year":"2022","journal-title":"Journal of Paediatrics and Child Health"},{"issue":"8","key":"10.1002\/14651858.CD016131-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"e0182321","DOI":"10.1371\/journal.pone.0182321","article-title":"The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review","volume":"12","author":"Colosia","year":"2017","journal-title":"PloS One"},{"issue":"2","key":"10.1002\/14651858.CD016131-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD016131-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ijid.2020.11.185","article-title":"Morbidity and mortality of respiratory syncytial virus infection in hospitalized adults: Comparison with seasonal influenza","volume":"103","author":"Atamna","year":"2021","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD016131-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-642-38919-1_4","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Current Topics in Microbiology and Immunology"},{"issue":"3","key":"10.1002\/14651858.CD016131-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3181\/00379727-92-22538","article-title":"Recovery of cytopathogenic agent from chimpanzees with coryza","volume":"92","author":"Morris","year":"1956","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"issue":"7830","key":"10.1002\/14651858.CD016131-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1002\/14651858.CD016131-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"American Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD016131-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"7958","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"181","author":"Olson","year":"2008","journal-title":"American Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD016131-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"e230023","DOI":"10.1001\/jamanetworkopen.2023.0023","article-title":"Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis","volume":"6","author":"Sun","year":"2023","journal-title":"JAMA Network Open"},{"issue":"16","key":"10.1002\/14651858.CD016131-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion f vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD016131-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion f protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD016131-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/vaccines11050999","article-title":"A first-in-human trial to evaluate the safety and immunogenicity of a g protein-based recombinant respiratory syncytial virus vaccine in healthy adults 18-45 years of age","volume":"11","author":"Cheng","year":"2023","journal-title":"Vaccines"},{"issue":"3","key":"10.1002\/14651858.CD016131-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/infdis\/jiy177","article-title":"A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study","volume":"218","author":"Langley","year":"2018","journal-title":"Journal of Infectious Diseases"},{"issue":"312","key":"10.1002\/14651858.CD016131-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"312ra175","DOI":"10.1126\/scitranslmed.aac8463","article-title":"A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children","volume":"7","author":"Karron","year":"2015","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016131-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/infdis\/jiac382","article-title":"An RSV live-attenuated vaccine candidate lacking g protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB\/c mice","volume":"227","author":"Roe","year":"2022","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD016131-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/infdis\/jiz408","article-title":"Safety and immunogenicity of the respiratory syncytial virus vaccine RSV\/DELTANS2\/DELTA1313\/I1314L in RSV seronegative children","volume":"222","author":"Karron","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"27","key":"10.1002\/14651858.CD016131-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"100517","DOI":"10.1016\/j.eclinm.2020.100517","article-title":"Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial","volume":"6","author":"Abarca","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1002\/14651858.CD016131-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/INF.0b013e31823386f1","article-title":"Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children","volume":"31","author":"Bernstein","year":"2012","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"5","key":"10.1002\/14651858.CD016131-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.vaccine.2011.11.046","article-title":"Sendai virus-based RSV vaccine protects African green monkeys from RSV infection","volume":"30","author":"Jones","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD016131-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/vaccines11020367","article-title":"Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine","volume":"11","author":"Leroux-Roels","year":"2023","journal-title":"Vaccines"},{"issue":"21","key":"10.1002\/14651858.CD016131-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.15585\/mmwr.mm7321a3.","article-title":"Early safety findings among persons aged \u226560 years who received a respiratory syncytial virus vaccine - United States, May 3, 2023-April 14, 2024","volume":"73","author":"Hause","year":"2024","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"16","key":"10.1002\/14651858.CD016131-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion f vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016131-BIB0031|cit31","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016131-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016131-BIB0033|cit33","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD016131-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016131-BIB0035|cit35","unstructured":"Covidence Veritas Health Innovation 2024"},{"key":"10.1002\/14651858.CD016131-BIB0036|cit36","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"355","key":"10.1002\/14651858.CD016131-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"12","author":"Sterne","year":"2016","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016131-BIB0038|cit38","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016131-BIB0039|cit39","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016131-BIB0040|cit40","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016131-BIB0041|cit41","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD016131-BIB0042|cit42","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016131-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"7","key":"10.1002\/14651858.CD016131-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"7650","key":"10.1002\/14651858.CD016131-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD016131-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016131-BIB0047|cit47","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD016131-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","article-title":"GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016131-BIB0049|cit49","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"issue":"5","key":"10.1002\/14651858.CD016131-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD016131-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV preF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD016131-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, postfusion f protein-based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"Journal of Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD016131-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2207566","article-title":"Efficacy and safety of an ad26.rsv.pref-RSV pref protein vaccine in older adults","volume":"388","author":"Falsey","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD016131-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/infdis\/jiv406","article-title":"A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age","volume":"213","author":"Glenn","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"17","key":"10.1002\/14651858.CD016131-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion f protein-based respiratory syncytial virus immunization in pregnancy","volume":"386","author":"Sim\u00f5es","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD016131-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/infdis\/jiy066","article-title":"Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children","volume":"217","author":"Buchholz","year":"2018","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD016131-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1093\/infdis\/jiac253","article-title":"Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV\/\u0394NS2\/\u03941313\/I1314L and RSV\/276 in RSV-seronegative children","volume":"226","author":"Cunningham","year":"2022","journal-title":"Journal of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD016131-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/infdis\/jiz603","article-title":"Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children","volume":"221","author":"McFarland","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD016131-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1093\/infdis\/jiaa049","article-title":"Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children","volume":"221","author":"McFarland","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD016131-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/infdis\/jiy040","article-title":"Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children","volume":"217","author":"McFarland","year":"2018","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD016131-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/cid\/ciad471","article-title":"Respiratory syncytial virus prefusion f protein vaccine is efficacious in older adults with underlying medical conditions","volume":"78","author":"Feldman","year":"2024","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD016131-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"e13236","DOI":"10.1111\/irv.13236","article-title":"The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults \u226560\u2009years of age","volume":"18","author":"Curran","year":"2024","journal-title":"Influenza and Other Respiratory Viruses"},{"issue":"6","key":"10.1002\/14651858.CD016131-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons","volume":"78","author":"Ison","year":"2024","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD016131-BIB0064|cit64","unstructured":"A study to evaluate the safety and efficacy of mRNA-1345 vaccine targeting respiratory syncytial virus (RSV) in adults \u226560 years of age https:\/\/clinicaltrials.gov\/study\/NCT05127434"},{"key":"10.1002\/14651858.CD016131-BIB0065|cit65","unstructured":"A study to evaluate the efficacy of MEDI7510 in older adults https:\/\/clinicaltrials.gov\/study\/NCT02508194"},{"issue":"12","key":"10.1002\/14651858.CD016131-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1093\/infdis\/jiac189","article-title":"A phase 1\/2 study of a respiratory syncytial virus prefusion f vaccine with and without adjuvant in healthy older adults","volume":"226","author":"Baber","year":"2022","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD016131-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1086\/425981","article-title":"Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children","volume":"190","author":"Belshe","year":"2004","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD016131-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"ofz212","DOI":"10.1093\/ofid\/ofz212","article-title":"Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is overattenuated","volume":"26","author":"Cunningham","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD016131-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"S27\u20138","DOI":"10.1093\/ofid\/ofz359.061","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the efficacy of a single immunization of ad26.rsv.pref against RSV infection in a viral challenge model in healthy adults","volume":"6","author":"DeVincenzo","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD016131-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","article-title":"RSV prefusion f protein-based maternal vaccine - preterm birth and other outcomes","volume":"390","author":"Dieussaert","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD016131-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"S921\u20132","DOI":"10.1093\/ofid\/ofz360.2315","article-title":"Third trimester immunization with an respiratory syncytial virus f protein vaccine for the prevention of RSV lower respiratory tract infection in infants","volume":"6","author":"Fries","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1002\/14651858.CD016131-BIB0072|cit72","unstructured":"A follow-up study to describe the safety of study participants who received rsvpref3 maternal vaccination (any dose) or controls from previous RSV MAT studies during any pregnancy conceived post vaccination\/\u200bcontrol ClinicalTrials.gov 2023 https:\/\/clinicaltrials.gov\/study\/NCT05705440"},{"key":"10.1002\/14651858.CD016131-BIB0073|cit73","unstructured":"A phase III study to assess the lot-to-lot consistency of gsk's investigational RSV maternal vaccine and the immune response and safety of RSV maternal vaccine when given alone or co-administered with gsk's influenza D-QIV vaccine in healthy non-pregnant women ClinicalTrials.gov 2024 https:\/\/clinicaltrials.gov\/study\/NCT05045144"},{"key":"10.1002\/14651858.CD016131-BIB0074|cit74","unstructured":"A study of 3 lots of an investigational vaccine against respiratory syncytial virus (RSV) in adults aged 60 years and above ClinicalTrials.gov 2024 https:\/\/clinicaltrials.gov\/study\/NCT05059301"},{"issue":"17","key":"10.1002\/14651858.CD016131-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/s0264-410x(99)00527-7","article-title":"Evaluation of the live attenuated cpts 248\/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults","volume":"18","author":"Gonzalez","year":"2000","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD016131-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jinf.2019.02.003","article-title":"Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults","volume":"78","author":"Green","year":"2019","journal-title":"Journal of Infection"},{"key":"10.1002\/14651858.CD016131-BIB0077|cit77","unstructured":"Janssen Pharmaceutical KK A study of adenovirus serotype 26.respiratory syncytial virus.pre-fusion f (ad26.rsv.pref)-based vaccine for prevention of respiratory syncytial virus (RSV) mediated- lower respiratory tract disease (LRTD) in Japanese participants ClinicalTrials.gov 2024 https:\/\/clinicaltrials.gov\/study\/NCT05242432"},{"key":"10.1002\/14651858.CD016131-BIB0078|cit78","unstructured":"Janssen Vaccines & Prevention BV A study of an ad26.rsv. pref-based vaccine in adults aged 18 to 59 years, including adults at high risk for severe RSV infection ClinicalTrials.gov 2023 https:\/\/clinicaltrials.gov\/study\/NCT05070546"},{"key":"10.1002\/14651858.CD016131-BIB0079|cit79","unstructured":"Janssen Vaccines & Prevention BV A study of an adenovirus serotype 26 pre-fusion conformation-stabilized f protein (ad26. RSV. pref) based respiratory syncytial virus (RSV) vaccine in the prevention of lower respiratory tract disease in adults aged 60 years and older (EVERGREEN) ClinicalTrials.gov 2024 https:\/\/clinicaltrials.gov\/study\/NCT04908683"},{"key":"10.1002\/14651858.CD016131-BIB0080|cit80","unstructured":"Janssen Vaccines & Prevention BV A study of various respiratory syncytial virus (RSV) pre-fusion (pref)-based vaccine formulations in adults aged 60 years and older ClinicalTrials.gov 2024 https:\/\/clinicaltrials.gov\/study\/NCT05327816"},{"issue":"8","key":"10.1002\/14651858.CD016131-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/infdis\/jiad108","article-title":"Reduced respiratory syncytial virus load, symptoms, and infections: a human challenge trial of MVA-BN-RSV vaccine","volume":"228","author":"Jordan","year":"2023","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD016131-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/infdis\/jiaa460","article-title":"Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus-based respiratory syncytial virus vaccine","volume":"223","author":"Jordan","year":"2021","journal-title":"Journal of Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD016131-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1086\/427813","article-title":"Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants","volume":"191","author":"Karron","year":"2005","journal-title":"Journal of Infectious Diseases"},{"issue":"42","key":"10.1002\/14651858.CD016131-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1016\/j.vaccine.2009.07.038","article-title":"A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age","volume":"27","author":"Langley","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD016131-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/vaccines11020367","article-title":"Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine","volume":"11","author":"Leroux-Roels","year":"2023","journal-title":"Vaccines"},{"issue":"3","key":"10.1002\/14651858.CD016131-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/infdis\/jiab003","article-title":"Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of ad26.rsv.pref in a human challenge study","volume":"226","author":"Sadoff","year":"2022","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD016131-BIB0087|cit87","unstructured":"Study of an live-attenuated respiratory syncytial virus vaccine in infants and toddlers (VAD00001) ClinicalTrials.gov 2023 https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04491877"},{"key":"10.1002\/14651858.CD016131-BIB0088|cit88","unstructured":"Efficacy, immunogenicity, and safety study of a respiratory syncytial virus vaccine in infants and toddlers (PEARL) ClinicalTrials.gov 2024 https:\/\/clinicaltrials.gov\/study\/NCT06252285"},{"issue":"24","key":"10.1002\/14651858.CD016131-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa2116154","article-title":"Vaccine efficacy in adults in a respiratory syncytial virus challenge study","volume":"386","author":"Schmoele-Thoma","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD016131-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/ofid\/ofac492.174","article-title":"A candidate respiratory syncytial virus (RSV) prefusion F protein investigational vaccine (RSVPreF3 OA) is immunogenic when administered in adults\u2265 60 years of age: results at 6 months after vaccination","volume":"9","author":"Schwarz","year":"2022","journal-title":"Open Forum Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD016131-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.ajog.2019.10.081","article-title":"Safety of third trimester immunization with a respiratory syncytial virus F protein vaccine and protection of infants over the first 180 days of life against all-cause lower respiratory tract infection","volume":"221","author":"Swamy","year":"2019","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"5","key":"10.1002\/14651858.CD016131-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/archdischild-2020-321368","article-title":"Respiratory syncytial virus vaccination in pregnancy is not effective enough at reducing infant infections","volume":"107","author":"Wesley","year":"2022","journal-title":"Archives of Disease in Childhood. Education and Practice Edition"},{"issue":"42","key":"10.1002\/14651858.CD016131-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"7372","DOI":"10.1016\/j.vaccine.2007.08.014","article-title":"The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines","volume":"25","author":"Wright","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD016131-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1086\/315859","article-title":"Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy","volume":"182","author":"Wright","year":"2000","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD016131-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jval.2019.09.2747","article-title":"Evaluation of efficacy endpoints for a phase iib study of a respiratory syncytial virus vaccine in older adults using patient-reported outcomes with laboratory confirmation","volume":"23","author":"Yu","year":"2020","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD016131-BIB0096|cit96","unstructured":"A phase III, double-blind study to assess safety and efficacy of an RSV maternal unadjuvanted vaccine, in pregnant women and infants born to vaccinated mothers (GRACE) ClinicalTrials.gov 2024 https:\/\/clinicaltrials.gov\/study\/NCT04605159"},{"key":"10.1002\/14651858.CD016131-BIB0097|cit97","unstructured":"FDA requires Guillain-Barr\u00e9 Syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy: FDA safety communication https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and"},{"issue":"3","key":"10.1002\/14651858.CD016131-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"e052943","DOI":"10.1136\/bmjopen-2021-052943","article-title":"Which outcomes should be used in future bronchiolitis trials? Developing a bronchiolitis core outcome set using a systematic review, Delphi survey and a consensus workshop","volume":"12","author":"Rosala-Hallas","year":"2022","journal-title":"BMJ Open"},{"issue":"5-6","key":"10.1002\/14651858.CD016131-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s0264-410x(01)00388-7","article-title":"Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines","volume":"20","author":"Simoes","year":"2001","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD016131-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12250-015-3630-3","article-title":"The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis","volume":"30","author":"Zhu","year":"2015","journal-title":"Virologica Sinica"},{"issue":"5","key":"10.1002\/14651858.CD016131-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015134.pub2","article-title":"Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes","author":"Phijffer","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD016131-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/irv.12850","article-title":"The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review","volume":"15","author":"Shan","year":"2021","journal-title":"Influenza and Other Respiratory Viruses"},{"issue":"3","key":"10.1002\/14651858.CD016131-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child and Adolescent Health"},{"issue":"2","key":"10.1002\/14651858.CD016131-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40121-014-0046-6","article-title":"Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review","volume":"3","author":"Wegzyn","year":"2014","journal-title":"Infectious Diseases and Therapy"},{"key":"10.1002\/14651858.CD016131-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1745-6215-13-132","article-title":"Developing core outcome sets for clinical trials: issues to consider","volume":"13","author":"Williamson","year":"2012","journal-title":"Trials"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:32:27Z","timestamp":1788499947000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016131"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":105,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016131","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}